Moolec Science Achieves Breakthrough Results Boosting Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy MLEC?
Source: Benzinga
Moolec Science SA's stock surged by 43.32% as it reached a 20-day high, reflecting strong investor interest following significant agricultural advancements.
The company reported a remarkable increase in safflower yields, achieving an average of 2,200 pounds per acre, up from 1,400 pounds in 2024. Additionally, Moolec confirmed gamma-linolenic acid (GLA) concentrations of around 45% from its GLASO safflower platform, validating its plant-engineered molecular farming technology. This operational success, combined with Nasdaq listing approval, has significantly boosted market confidence and investor optimism regarding Moolec's growth prospects.
These developments position Moolec Science favorably in the market, indicating a strong potential for sustainable revenue growth and reinforcing investor confidence in its innovative agricultural solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLEC
About MLEC
Moolec Science SA is a science based food ingredient company. The Company focuses on the production of animal proteins within plants by using molecular farming technology. It operates globally across the United States, Europe, and South America. The Company’s product portfolio and pipeline focus on improving the agronomic efficiency of widely used crops such as soy, pea, and safflower. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. The Company’s GLASO product is a genetically engineered safflower variety designed to produce higher levels of gamma linolenic acid (GLA). Its PIGGY SOOY product is a bioengineered soybean that contains pig proteins used in creating meat like textures and food ingredients. The Company also has a growing international patent portfolio of approximately 25 patents, both granted and pending, for its technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
Moolec Achieves Breakthrough Results and Stock Market Reaction
- Increased Planting and Yields: Moolec cultivated approximately 1,100 acres of engineered safflower in the 2025 season, achieving an average yield of 2,200 pounds per acre, significantly up from 1,400 pounds in 2024, exceeding the company's expectations and demonstrating the effectiveness and potential of its agricultural technology.
- GLA Concentration Validation: The company confirmed gamma-linolenic acid (GLA) concentrations of around 45% from its U.S. GLASO safflower platform, marking the operational feasibility of its plant-engineered molecular farming technology for commercial-scale production, laying the groundwork for sustainable revenue.
- Nasdaq Listing Approval: On January 30, Moolec confirmed that the Nasdaq Hearings Panel approved its request for continued listing after the company regained compliance with minimum bid price requirements following a one-for-15 reverse stock split, boosting market confidence.
- Positive Stock Market Reaction: Following the announcement of strong crushing results, Moolec's shares soared over 130% on Friday, with the stock gaining 241% year-to-date, reflecting strong investor optimism regarding its future growth prospects.
See More
U.S. Stocks Rise as Inflation Eases
- Market Performance: U.S. stocks traded higher, with the Dow Jones gaining approximately 250 points, or 0.50%, closing at 49,701.48, indicating optimistic market sentiment regarding economic recovery.
- Inflation Data: The annual consumer price inflation rate in the U.S. eased to 2.4% in January 2026 from 2.7% in December, falling below economists' expectations of 2.5%, marking the lowest inflation level since May 2025, which may influence the Federal Reserve's monetary policy decisions.
- Sector Dynamics: Utility stocks rose by 2% on Friday, while financial stocks fell by 0.3%, reflecting mixed reactions across different sectors that could impact investors' asset allocation strategies.
- International Market Reaction: Asian markets closed lower, with Japan's Nikkei down 1.21% and Hong Kong's Hang Seng Index down 1.72%, indicating that global economic uncertainties may negatively affect investor sentiment.
See More
Moolec Science Stock Surges on Strong GLASO Results
- Oil Yield Increase: Moolec Science's GLASO program produced oil with approximately 45% gamma-linolenic acid after standard U.S. crushing, marking one of the highest levels reported at commercial scale, showcasing the product's market competitiveness.
- Expanded Cultivation: The company cultivated about 1,100 acres of engineered safflower in its 2025 campaign, achieving average yields near 2,200 pounds per acre, a 57% year-over-year increase from roughly 1,400 pounds per acre in 2024, indicating significant enhancement in agricultural production capacity.
- Commercial Validation: Management stated that these results validate the platform's ability to operate through existing U.S. agricultural and industrial infrastructure, a key step toward repeatable commercial production, which boosts investor confidence.
- Positive Market Reaction: In early trading, MLEC shares surged approximately 118% to $11.12, reflecting investor optimism regarding the company's execution-led growth strategy, particularly its recurring revenue targets in the nutrition and dietary supplements market.
See More
U.S. Stocks Decline in Morning Trade as Inflation Rate Eases
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index falling approximately 0.1% to 49,387.55, indicating a cautious market sentiment regarding economic outlook.
- Sector Dynamics: Utility stocks gained 1.5%, while communication services stocks fell by 0.6%, reflecting a divergence in market performance across sectors that could influence investors' asset allocation strategies.
- Earnings Highlights: Advance Auto Parts (NYSE:AAP) reported better-than-expected fourth-quarter results, with earnings per share of $0.86 surpassing the analyst consensus of $0.42, and sales reaching $1.973 billion, demonstrating the company's strong performance in a competitive market.
- Economic Data: The annual inflation rate eased to 2.4% in January, the lowest level since May, down from 2.7% in the previous month, which may impact the Federal Reserve's monetary policy decisions.
See More
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
Moolec Achieves Breakthrough Results and Stock Market Reaction
- Increased Planting and Yields: Moolec cultivated approximately 1,100 acres of engineered safflower in the 2025 season, achieving an average yield of 2,200 pounds per acre, significantly up from 1,400 pounds in 2024, exceeding the company's expectations and demonstrating the effectiveness and potential of its agricultural technology.
- GLA Concentration Validation: The company confirmed gamma-linolenic acid (GLA) concentrations of around 45% from its U.S. GLASO safflower platform, marking the operational feasibility of its plant-engineered molecular farming technology for commercial-scale production, laying the groundwork for sustainable revenue.
- Nasdaq Listing Approval: On January 30, Moolec confirmed that the Nasdaq Hearings Panel approved its request for continued listing after the company regained compliance with minimum bid price requirements following a one-for-15 reverse stock split, boosting market confidence.
- Positive Stock Market Reaction: Following the announcement of strong crushing results, Moolec's shares soared over 130% on Friday, with the stock gaining 241% year-to-date, reflecting strong investor optimism regarding its future growth prospects.
See More
U.S. Stocks Rise as Inflation Eases
- Market Performance: U.S. stocks traded higher, with the Dow Jones gaining approximately 250 points, or 0.50%, closing at 49,701.48, indicating optimistic market sentiment regarding economic recovery.
- Inflation Data: The annual consumer price inflation rate in the U.S. eased to 2.4% in January 2026 from 2.7% in December, falling below economists' expectations of 2.5%, marking the lowest inflation level since May 2025, which may influence the Federal Reserve's monetary policy decisions.
- Sector Dynamics: Utility stocks rose by 2% on Friday, while financial stocks fell by 0.3%, reflecting mixed reactions across different sectors that could impact investors' asset allocation strategies.
- International Market Reaction: Asian markets closed lower, with Japan's Nikkei down 1.21% and Hong Kong's Hang Seng Index down 1.72%, indicating that global economic uncertainties may negatively affect investor sentiment.
See More
Moolec Science Stock Surges on Strong GLASO Results
- Oil Yield Increase: Moolec Science's GLASO program produced oil with approximately 45% gamma-linolenic acid after standard U.S. crushing, marking one of the highest levels reported at commercial scale, showcasing the product's market competitiveness.
- Expanded Cultivation: The company cultivated about 1,100 acres of engineered safflower in its 2025 campaign, achieving average yields near 2,200 pounds per acre, a 57% year-over-year increase from roughly 1,400 pounds per acre in 2024, indicating significant enhancement in agricultural production capacity.
- Commercial Validation: Management stated that these results validate the platform's ability to operate through existing U.S. agricultural and industrial infrastructure, a key step toward repeatable commercial production, which boosts investor confidence.
- Positive Market Reaction: In early trading, MLEC shares surged approximately 118% to $11.12, reflecting investor optimism regarding the company's execution-led growth strategy, particularly its recurring revenue targets in the nutrition and dietary supplements market.
See More
U.S. Stocks Decline in Morning Trade as Inflation Rate Eases
- Market Performance: U.S. stocks traded lower this morning, with the Dow Jones index falling approximately 0.1% to 49,387.55, indicating a cautious market sentiment regarding economic outlook.
- Sector Dynamics: Utility stocks gained 1.5%, while communication services stocks fell by 0.6%, reflecting a divergence in market performance across sectors that could influence investors' asset allocation strategies.
- Earnings Highlights: Advance Auto Parts (NYSE:AAP) reported better-than-expected fourth-quarter results, with earnings per share of $0.86 surpassing the analyst consensus of $0.42, and sales reaching $1.973 billion, demonstrating the company's strong performance in a competitive market.
- Economic Data: The annual inflation rate eased to 2.4% in January, the lowest level since May, down from 2.7% in the previous month, which may impact the Federal Reserve's monetary policy decisions.
See More
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
